Psoriatic Arthritis Clinical Trials 2024

Psoriatic Arthritis Clinical Trials 2024

Psoriatic Arthritis research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in psoriatic arthritis clinical trials today.

Psoriatic Arthritis Clinical Trials

Here are the 6 most popular medical studies for psoriatic arthritis

Popular filter options for psoriatic arthritis trials

PsA Clinical Trials

View 32 PsA medical studies.

Phase 3 Psoriatic Arthritis Clinical Trials

View 34 phase 3 psoriatic arthritis medical studies.

Psoriatic Arthritis Clinical Trials With No Placebo

View 34 psoriatic arthritis medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to psoriatic arthritis

What are the top hospitals conducting psoriatic arthritis research?

When it comes to cutting-edge research and clinical trials for psoriatic arthritis, hospitals across the United States are actively working to find new treatment options. In Philadelphia, the University of Pennsylvania is leading the way with four ongoing trials focused on psoriatic arthritis. This renowned institution has a total of four recorded trials in this field since they started their first investigation in 2019. Down in Tomball, Texas, DM Clinical Research is also making significant contributions with four active psoriatic arthritis trials and a matching tally of completed studies since their inaugural trial in 2020.

Moving westward to Phoenix, Arizona Arthritis and Rheumatology Research, PLLC is dedicated to advancing knowledge about psoriatic arthritis through three ongoing clinical trials. With a relatively recent start date in 2021, this institute shows promise as they continue their efforts towards better understanding and treating this condition. Similarly committed to researching psoriatic arthritis are the healthcare professionals at Bay Pines VA Healthcare System in Bay Pines, Florida. They too have three active clinical trials focused on this specific form of arthritis dating back to 2021.

Finally, located beachside in Huntington Beach, California's Newport Huntington Medical Group joins the ranks with three current psoriatic arthritis trials under its belt since recording its first trial also just last year (in 2021). These hospitals may vary geographically but share a common goal: improving the lives of those affected by psoriatic arthritis through groundbreaking research.

Psoriatic arthritis affects millions around the world—an inflammatory condition that causes joint pain and stiffness often accompanied by skin changes like patches or scales. As researchers delve deeper into these clinical investigations across different locations within America's medical landscape; they bring hope not only for patients themselves but also for future generations who will benefit from advancements made today

Which are the best cities for psoriatic arthritis clinical trials?

In the realm of psoriatic arthritis clinical trials, several cities stand out as hubs for research and development. Phoenix, Arizona takes the lead with 17 active studies focusing on promising treatments like Upadacitinib, Guselkumab, and TILD. Tampa, Florida follows closely behind with 13 ongoing trials investigating medications such as Upadacitinib, Risankizumab, and Guselkumab. Duncansville in Pennsylvania also shows promise with 11 active trials exploring options like Risankizumab and Upadacitinib. While New york City and Mesquite in Texas each host 10 ongoing studies targeting various medications including Ustekinumab, Nivolumab, Guselkumab, VTX958 Dose A among others. These cities serve as beacons of hope for individuals seeking participation in cutting-edge psoriatic arthritis clinical trials that may pave the path towards improved treatment outcomes.

Which are the top treatments for psoriatic arthritis being explored in clinical trials?

Clinical trials are paving the way for advancements in the treatment of psoriatic arthritis. Among the top contenders are guselkumab and ustekinumab, both currently involved in multiple active trials. Guselkumab has shown promise with four ongoing studies and a total of 12 psoriatic arthritis trials since its introduction in 2013. Ustekinumab, on the other hand, is being tested in three active trials and has accumulated 11 all-time trials dedicated to this condition since its listing seven years ago. Newcomer deucravacitinib is also making waves with two current clinical trials, having entered the scene just this year. Additionally, TILD and risankizumab show potential as they each participate in two active psoriatic arthritis studies. These treatments offer hope for improving outcomes and quality of life for individuals living with this challenging condition.

What are the most recent clinical trials for psoriatic arthritis?

Exciting advancements in the treatment of psoriatic arthritis have emerged from recent clinical trials. Notably, GUS has entered Phase 3, offering hope for improved outcomes and relief for patients with this condition. In addition, guselkumab prefilled syringe (Tremfya) has also shown promise in Phase 3 trials as a potential therapy for psoriatic arthritis patients. Another noteworthy development is VTX958 Dose A, which has progressed to Phase 2 trials. Lastly, sonelokimab dose regimen 1 and Group 1 are both undergoing Phase 2 and Phase 3 testing respectively. These groundbreaking studies bring us closer to more effective treatments that can significantly enhance the lives of individuals living with psoriatic arthritis.

What psoriatic arthritis clinical trials were recently completed?

Recent clinical trials have made significant strides in the field of psoriatic arthritis, offering hope for improved treatments. Takeda's trial investigating NDI-034858 concluded in January 2022, while UCB Biopharma SRL completed two trials: one on certolizumab pegol pharmacokinetics in June 2020 and another on Bimekizumab in April 2019. Additionally, Amgen's trial exploring Apremilast (CC-10004) wrapped up its research in December 2018. These advancements showcase the commitment of researchers to addressing the challenges posed by psoriatic arthritis and provide valuable insights into potential therapeutic options for patients affected by this condition.